Skip to main content
Erschienen in: Hepatology International 6/2020

28.12.2020 | Original Article

A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC

verfasst von: Xia Sheng, Yuan Ji, Guo-Ping Ren, Chang-Li Lu, Jing-Ping Yun, Li-Hong Chen, Bin Meng, Li-Juan Qu, Guang-Jie Duan, Qing Sun, Xin-Qing Ye, Shan-Shan Li, Jing Yang, Bing Liao, Zhan-Bo Wang, Jian-Hua Zhou, Yu Sun, Xue-Shan Qiu, Lei Wang, Zeng-Shan Li, Jun Chen, Chun-Yan Xia, Song He, Chuan-Ying Li, En-Wei Xu, Jing-Shu Geng, Chao Pan, Dong Kuang, Rong Qin, Hong-Wei Guan, Zhan-Dong Wang, Li-Xing Li, Xi Zhang, Han Wang, Qian Zhao, Bo Wei, Wu-Jian Zhang, Shao-Ping Ling, Xiang Du, Wen-Ming Cong, for the Liver Cancer Pathology Group of China (LCPGC)

Erschienen in: Hepatology International | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Microvascular invasion (MVI) is a key pathological factor that severely affects the postoperative prognosis of patients with hepatocellular carcinoma (HCC). However, no MVI classification schemes based on standardized gross sampling protocols of HCC are available at present.

Methods

119 HCC specimens were sampled at multiple sites (3-, 7-, and 13 points) for the optimum MVI detection rate. 16,144 resected HCCs were graded as M0, M1 or M2 by adopting three-tiered MVI grading (MVI-TTG) scheme based on the seven-point sampling protocol (SPSP). Survival analyses were performed on 2573 patients to explore the advantages of MVI-TTG.

Results

The MVI detection rate determined by SPSP was significantly higher than that determined by the 3-point sampling method (34.5% vs. 47.1%, p = 0.048), but was similar to that determined by the 13-point sampling method (47.1% vs. 51.3%, p = 0.517). Among 16,144 resected HCCs, the proportions of M0, M1 and M2 specimens according to SPSP were 53.4%, 26.2% and 20.4%, respectively. Postoperative survival analysis in 2573 HCC patients showed that the 3-year recurrence rates in M0, M1 and M2 MVI groups were 62.5%, 71.6% and 86.1%, respectively (p < 0.001), and the corresponding 3-year overall survival (OS) rates were 94.1%, 87.5% and 67.0%, respectively (p < 0.001). M1 grade was associated with early recurrence, while M2 grade was associated with both early and late recurrence. MVI-TTG had a larger area under the curve and net benefit rate than the two-tiered MVI grading scheme for predicting time to recurrence and OS.

Conclusions

SPSP is a practical method to balance the efficacy of sampling numbers and MVI detection rates. MVI-TTG based on SPSP is a better prognostic predictor than the two-tiered MVI scheme. The combined use of SPSP and MVI-TTG is recommended for the routine pathological diagnosis of HCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
Zurück zum Zitat Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2019;394:1145–1158.CrossRef Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2019;394:1145–1158.CrossRef
3.
Zurück zum Zitat Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.PubMedCrossRef Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.PubMedCrossRef
4.
Zurück zum Zitat Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2018;30:571–579.PubMedPubMedCentralCrossRef Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2018;30:571–579.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67:273–289.PubMedCrossRef Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67:273–289.PubMedCrossRef
6.
7.
Zurück zum Zitat Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284–1293.PubMedCrossRef Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284–1293.PubMedCrossRef
8.
Zurück zum Zitat Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology (Baltimore, MD). 2015;61:191–199.CrossRef Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology (Baltimore, MD). 2015;61:191–199.CrossRef
9.
Zurück zum Zitat Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol. 2018;24:4000–4013.PubMedPubMedCentralCrossRef Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol. 2018;24:4000–4013.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Wang H, Qian YW, Wu MC, Cong WM. Liver resection is justified in patients with BCLC intermediate stage hepatocellular carcinoma without microvascular invasion. J. Gastrointest. Surg. 2020;24(12):2737–47. Wang H, Qian YW, Wu MC, Cong WM. Liver resection is justified in patients with BCLC intermediate stage hepatocellular carcinoma without microvascular invasion. J. Gastrointest. Surg. 2020;24(12):2737–47.
11.
Zurück zum Zitat Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375–1382.PubMedCrossRef Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375–1382.PubMedCrossRef
12.
Zurück zum Zitat Imai K, Yamashita YI, Yusa T, Nakao Y, Itoyama R, Nakagawa S, et al. Microvascular invasion in small-sized hepatocellular carcinoma: significance for outcomes following hepatectomy and radiofrequency ablation. Anticancer Res. 2018;38(2):1053–1060.PubMed Imai K, Yamashita YI, Yusa T, Nakao Y, Itoyama R, Nakagawa S, et al. Microvascular invasion in small-sized hepatocellular carcinoma: significance for outcomes following hepatectomy and radiofrequency ablation. Anticancer Res. 2018;38(2):1053–1060.PubMed
13.
Zurück zum Zitat Xiao H, Chen ZB, Jin HL, Li B, Xu LX, Guo Y, et al. Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Am J Transl Res. 2019;11:1864–1875.PubMedPubMedCentral Xiao H, Chen ZB, Jin HL, Li B, Xu LX, Guo Y, et al. Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Am J Transl Res. 2019;11:1864–1875.PubMedPubMedCentral
14.
Zurück zum Zitat Hu HT, Wang Z, Kuang M, Wang W. Need for normalization: the non-standard reference standard for microvascular invasion diagnosis in hepatocellular carcinoma. World J Surg Oncol. 2018;16:50.PubMedPubMedCentralCrossRef Hu HT, Wang Z, Kuang M, Wang W. Need for normalization: the non-standard reference standard for microvascular invasion diagnosis in hepatocellular carcinoma. World J Surg Oncol. 2018;16:50.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, et al. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther. 2007;26:821–830.PubMedCrossRef Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, et al. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther. 2007;26:821–830.PubMedCrossRef
16.
Zurück zum Zitat Gill US, Pallett LJ, Kennedy PTF, Maini MK. Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut. 2018;67:767–775.PubMed Gill US, Pallett LJ, Kennedy PTF, Maini MK. Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut. 2018;67:767–775.PubMed
17.
Zurück zum Zitat Pons E, Braun LM, Hunink MG, Kors JA. Natural language processing in radiology: a systematic review. Radiology. 2016;279:329–343.PubMedCrossRef Pons E, Braun LM, Hunink MG, Kors JA. Natural language processing in radiology: a systematic review. Radiology. 2016;279:329–343.PubMedCrossRef
18.
Zurück zum Zitat Murff HJ, FitzHenry F, Matheny ME, Gentry N, Kotter KL, Crimin K, et al. Automated identification of postoperative complications within an electronic medical record using natural language processing. JAMA. 2011;306:848–855.PubMed Murff HJ, FitzHenry F, Matheny ME, Gentry N, Kotter KL, Crimin K, et al. Automated identification of postoperative complications within an electronic medical record using natural language processing. JAMA. 2011;306:848–855.PubMed
20.
Zurück zum Zitat Yim W, Yetisgen M, Harris WP, Kwan SW. Natural language processing in oncology: a review. JAMA Oncol. 2016;2:797–804.PubMedCrossRef Yim W, Yetisgen M, Harris WP, Kwan SW. Natural language processing in oncology: a review. JAMA Oncol. 2016;2:797–804.PubMedCrossRef
21.
Zurück zum Zitat Torbenson MS. Liver. In. Westra WH, Phelps TH, Hruban RH, Isacson C. Surgical Pathology Dissection. An Illustrated Guide. 2nd Ed, Springer-Verlag New York Inc, 2003;76–81. Torbenson MS. Liver. In. Westra WH, Phelps TH, Hruban RH, Isacson C. Surgical Pathology Dissection. An Illustrated Guide. 2nd Ed, Springer-Verlag New York Inc, 2003;76–81.
22.
Zurück zum Zitat Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22:9279–9287.PubMedPubMedCentralCrossRef Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22:9279–9287.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Zhou XD, Tang ZY, Ma ZC, Fan J, Wu ZQ, Qin LX, et al. Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. J Cancer Res Clin Oncol. 2009;135:1067–1072.PubMedCrossRef Zhou XD, Tang ZY, Ma ZC, Fan J, Wu ZQ, Qin LX, et al. Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. J Cancer Res Clin Oncol. 2009;135:1067–1072.PubMedCrossRef
25.
Zurück zum Zitat Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–113.PubMedCrossRef Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–113.PubMedCrossRef
26.
Zurück zum Zitat Du M, Chen L, Zhao J, Tian F, Zeng H, Tan Y, et al. Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer. 2014;14:38.PubMedPubMedCentralCrossRef Du M, Chen L, Zhao J, Tian F, Zeng H, Tan Y, et al. Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer. 2014;14:38.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Wang H, Wu MC, Cong WM. Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis. Hepatol Res. 2019;49:344–354.PubMedCrossRef Wang H, Wu MC, Cong WM. Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis. Hepatol Res. 2019;49:344–354.PubMedCrossRef
28.
Zurück zum Zitat Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24:2074–2081.PubMedCrossRef Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24:2074–2081.PubMedCrossRef
29.
Zurück zum Zitat Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (London). 2018;38(1):61.CrossRef Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (London). 2018;38(1):61.CrossRef
30.
Zurück zum Zitat EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef
31.
Zurück zum Zitat Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, MD). 2018;67:358–380.CrossRef Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, MD). 2018;67:358–380.CrossRef
32.
Zurück zum Zitat Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.PubMedCrossRef Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.PubMedCrossRef
33.
Zurück zum Zitat Chen ZH, Zhang XP, Wang H, Chai ZT, Sun JX, Guo WX, et al. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. HPB. 2019;21:935–944.PubMedCrossRef Chen ZH, Zhang XP, Wang H, Chai ZT, Sun JX, Guo WX, et al. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. HPB. 2019;21:935–944.PubMedCrossRef
34.
Zurück zum Zitat Huo TI, Liu PH, Hsu CY. Detecting microvascular invasion in HCC with contrast-enhanced MRI: is it a good idea? J Hepatol. 2018;68:862–263.PubMedCrossRef Huo TI, Liu PH, Hsu CY. Detecting microvascular invasion in HCC with contrast-enhanced MRI: is it a good idea? J Hepatol. 2018;68:862–263.PubMedCrossRef
35.
Zurück zum Zitat Cong WM, Dong H, Zhu YY, et al. Malignant tumors of the liver and intrahepatic bile ducts. In: Cong WM. Surgical pathology of hepatobiliary tumors. 1st ed. Springer Nature Singapore Pte Ltd. and People’s Medical Publishing House; 2017:145–282 Cong WM, Dong H, Zhu YY, et al. Malignant tumors of the liver and intrahepatic bile ducts. In: Cong WM. Surgical pathology of hepatobiliary tumors. 1st ed. Springer Nature Singapore Pte Ltd. and People’s Medical Publishing House; 2017:145–282
36.
Zurück zum Zitat Fujita N, Aishima S, Iguchi T, Mano Y, Taketomi A, Shirabe K, et al. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Hum Pathol. 2011;42:1531–1538.PubMedCrossRef Fujita N, Aishima S, Iguchi T, Mano Y, Taketomi A, Shirabe K, et al. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Hum Pathol. 2011;42:1531–1538.PubMedCrossRef
37.
Zurück zum Zitat Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–855.PubMedCrossRef Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–855.PubMedCrossRef
38.
Zurück zum Zitat Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1002–1009.PubMedCrossRef Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1002–1009.PubMedCrossRef
39.
Zurück zum Zitat Hidaka M, Eguchi S, Okuda K, Beppu T, Shirabe K, Kondo K, et al. Impact of anatomical resection for hepatocellular carcinoma with microportal invasion (vp1): a multi-institutional study by the kyushu study group of liver surgery. Ann Surg. 2020;271(2):339–346.PubMedCrossRef Hidaka M, Eguchi S, Okuda K, Beppu T, Shirabe K, Kondo K, et al. Impact of anatomical resection for hepatocellular carcinoma with microportal invasion (vp1): a multi-institutional study by the kyushu study group of liver surgery. Ann Surg. 2020;271(2):339–346.PubMedCrossRef
40.
Zurück zum Zitat Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels. Hepato-Pancreato-Biliary Surg. 1996;10(2):97–103.CrossRef Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels. Hepato-Pancreato-Biliary Surg. 1996;10(2):97–103.CrossRef
41.
Zurück zum Zitat Park NH, Chung YH, Youn KH, Song BC, Yang SH, Kim JA, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol. 2001;33:397–401.PubMedCrossRef Park NH, Chung YH, Youn KH, Song BC, Yang SH, Kim JA, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol. 2001;33:397–401.PubMedCrossRef
42.
Zurück zum Zitat Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26:1474–1493.PubMedCrossRef Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26:1474–1493.PubMedCrossRef
43.
Zurück zum Zitat Feng LH, Dong H, Lau WY, Yu H, Zhu YY, Zhao Y, et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:293–303.PubMedCrossRef Feng LH, Dong H, Lau WY, Yu H, Zhu YY, Zhao Y, et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:293–303.PubMedCrossRef
44.
Zurück zum Zitat Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721.PubMedPubMedCentralCrossRef Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg. 2013;217:1054–1062.PubMedCrossRef Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg. 2013;217:1054–1062.PubMedCrossRef
46.
Zurück zum Zitat Wang H, Feng LH, Qian YW, Cao ZY, Wu MC, Cong WM. Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior? Ann Transl Med. 2019;7(18):428.PubMedPubMedCentralCrossRef Wang H, Feng LH, Qian YW, Cao ZY, Wu MC, Cong WM. Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior? Ann Transl Med. 2019;7(18):428.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Wang H, Du PC, Wu MC, Cong WM. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr. 2018;7:418–428.PubMedPubMedCentralCrossRef Wang H, Du PC, Wu MC, Cong WM. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr. 2018;7:418–428.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Yang P, Si A, Yang J, Cheng Z, Wang K, Li J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery. 2019;165:721–730.PubMedCrossRef Yang P, Si A, Yang J, Cheng Z, Wang K, Li J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery. 2019;165:721–730.PubMedCrossRef
49.
Zurück zum Zitat Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Impact of surgical margin on the prognosis of early hepatocellular carcinoma (≤5 cm): a propensity score matching analysis. Front Med 2020;7(139). Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Impact of surgical margin on the prognosis of early hepatocellular carcinoma (≤5 cm): a propensity score matching analysis. Front Med 2020;7(139).
50.
Zurück zum Zitat Wang L, Wang W, Yao X, Rong W, Wu F, Chen B, et al. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion. Oncotarget. 2017;8:79971–79981.PubMedPubMedCentralCrossRef Wang L, Wang W, Yao X, Rong W, Wu F, Chen B, et al. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion. Oncotarget. 2017;8:79971–79981.PubMedPubMedCentralCrossRef
Metadaten
Titel
A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC
verfasst von
Xia Sheng
Yuan Ji
Guo-Ping Ren
Chang-Li Lu
Jing-Ping Yun
Li-Hong Chen
Bin Meng
Li-Juan Qu
Guang-Jie Duan
Qing Sun
Xin-Qing Ye
Shan-Shan Li
Jing Yang
Bing Liao
Zhan-Bo Wang
Jian-Hua Zhou
Yu Sun
Xue-Shan Qiu
Lei Wang
Zeng-Shan Li
Jun Chen
Chun-Yan Xia
Song He
Chuan-Ying Li
En-Wei Xu
Jing-Shu Geng
Chao Pan
Dong Kuang
Rong Qin
Hong-Wei Guan
Zhan-Dong Wang
Li-Xing Li
Xi Zhang
Han Wang
Qian Zhao
Bo Wei
Wu-Jian Zhang
Shao-Ping Ling
Xiang Du
Wen-Ming Cong
for the Liver Cancer Pathology Group of China (LCPGC)
Publikationsdatum
28.12.2020
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 6/2020
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-020-10111-4

Weitere Artikel der Ausgabe 6/2020

Hepatology International 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.